Earl Martin Douglas Sells 6,404 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Earl Martin Douglas sold 6,404 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $1.71, for a total value of $10,950.84. Following the completion of the sale, the senior vice president now directly owns 587,848 shares of the company’s stock, valued at approximately $1,005,220.08. This represents a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Allogene Therapeutics Stock Down 2.4 %

ALLO stock opened at $1.60 on Friday. The company has a market cap of $335.47 million, a price-to-earnings ratio of -1.03 and a beta of 0.83. Allogene Therapeutics, Inc. has a 12-month low of $1.60 and a 12-month high of $5.78. The company has a 50 day moving average of $2.03 and a two-hundred day moving average of $2.44.

Hedge Funds Weigh In On Allogene Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALLO. Zacks Investment Management acquired a new position in shares of Allogene Therapeutics during the 3rd quarter valued at about $1,446,000. Dimensional Fund Advisors LP lifted its position in Allogene Therapeutics by 24.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock worth $5,944,000 after acquiring an additional 507,021 shares during the last quarter. Geode Capital Management LLC increased its position in Allogene Therapeutics by 14.4% in the 3rd quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock worth $9,037,000 after buying an additional 407,070 shares during the period. abrdn plc bought a new position in Allogene Therapeutics during the fourth quarter worth $776,000. Finally, The Manufacturers Life Insurance Company raised its position in shares of Allogene Therapeutics by 70.3% during the second quarter. The Manufacturers Life Insurance Company now owns 480,381 shares of the company’s stock valued at $1,119,000 after buying an additional 198,231 shares during the last quarter. Institutional investors own 83.63% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. William Blair reiterated an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of Allogene Therapeutics in a research note on Friday, November 8th. Finally, Piper Sandler dropped their price target on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.73.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).